A recent healthcare study has determined that initiating antiviral treatments early in chronic hepatitis B patients, specifically those in an indeterminate phase with high viral loads and normal liver enzyme levels, is cost-effective compared to delaying therapy until the disease progresses to chronic hepatitis.
Study Methodology Evaluates Treatment Timing
Researchers conducted a cost-utility analysis using a Markov model to compare the incremental cost-effectiveness ratio (ICER) of starting antiviral therapy during the indeterminate phase versus postponing treatment. The study simulated a cohort of 10,000 patients over a decade, incorporating data from a multicenter historical cohort in Korea. Key parameters included HBV DNA levels, ALT levels, and HBeAg status.
Findings Support Early Antiviral Intervention
The results revealed that initiating treatment in the indeterminate phase resulted in an ICER of US$12,050 per quality-adjusted life-year (QALY), well below the local willingness-to-pay threshold of US$25,000/QALY. From a societal perspective, early treatment not only proved cost-effective but also reduced overall costs. Additionally, a U-shaped relationship between baseline HBV DNA levels and ICER highlighted that patients with HBV DNA levels between 6-7 log₁₀ IU/mL experienced the most favorable cost-effectiveness.
- Starting treatment at HBV DNA levels of 6-7 log₁₀ IU/mL minimizes cost per QALY at US$2,018.
- Early intervention leads to lower long-term healthcare expenses from a societal viewpoint.
- Higher HBV DNA levels are associated with increased hepatocellular carcinoma risk, influencing cost-effectiveness outcomes.
Implementing early antiviral therapy for patients in the high-viremia indeterminate phase of chronic hepatitis B can optimize healthcare resource allocation and enhance patient prognosis. By preventing disease progression and reducing the incidence of hepatocellular carcinoma, healthcare systems may achieve significant cost savings and improve overall public health outcomes. Healthcare providers should consider HBV DNA levels and other risk factors when deciding on the timing of antiviral interventions to ensure both economic and clinical benefits.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
